Cargando…
A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia
Targeted therapy of chronic myeloid leukemia is currently based on small-molecule inhibitors that directly bind the tyrosine kinase domain of BCR-ABL1. This strategy has generally been successful, but is subject to drug resistance due to point mutations in the kinase domain. Kinase activity requires...
Autores principales: | Woessner, David W., Eiring, Anna M., Bruno, Benjamin J., Zabriskie, Matthew S., Reynolds, Kimberly R., Miller, Geoffrey D., O’Hare, Thomas, Deininger, Michael W., Lim, Carol S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621806/ https://www.ncbi.nlm.nih.gov/pubmed/25721898 http://dx.doi.org/10.1038/leu.2015.53 |
Ejemplares similares
-
Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015) -
Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017) -
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
por: Zabriskie, M S, et al.
Publicado: (2016) -
A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016) -
Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML
por: Lima, Maria Carolina P., et al.
Publicado: (2023)